The Ability of CMV-Specific Elispot Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients
Year: 2017
Type: article
Study design: Observational Study
Abstract: Background: CMV infection causes significant morbidity and mortality after allogeneic hematopoietic cell transplantation (allo-HCT). CMV cell mediated immunity, as assessed by T cells production of interferon gamma (IFN-γ) and other cytokines, is considered a major pathway to control CMV replication. We aimed to evaluate the ability of a CMV-specific ELISPOT assay (T-SPOT®.CMV, Oxford Diagnostics Laboratories®, Memphis, TN) to predict the outcome of low-level CMV reactivation in allo-HCT recipients.
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2590350868